{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:44:44Z","timestamp":1793051084168,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031962","name":"Walgreens Boots Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111645","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:33:33Z","timestamp":1781800413000},"page":"111645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort"],"prefix":"10.1016","volume":"222","author":[{"given":"Daniela","family":"Greto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Ratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stellamans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Peulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hemmatazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e8tra","family":"Braam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Ivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelagia","family":"Tsoutsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalla","family":"Santa Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Sancho-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111645_b0005","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0015","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016\/S0140-6736(23)01857-3. Epub 2023 Dec 14. PMID: 38104577; PMCID: PMC10880046."},{"key":"10.1016\/j.radonc.2026.111645_b0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ijrobp.2022.07.012","article-title":"The impact of disease progression on health-related quality of life outcomes in patients with oligometastatic disease at 12 months post stereotactic body radiation therapy","volume":"114","author":"Barry","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111645_b0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11764-020-00869-9","article-title":"Quality of life in \u201cchronic\u201d cancer survivors: a meta-analysis","volume":"14","author":"Firkins","year":"2020","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.radonc.2026.111645_b0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2022.05.033","article-title":"Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: a systematic review and individual patient data meta-analysis","volume":"173","author":"Barry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110235","article-title":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study","volume":"195","author":"Christ","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111645_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115235","article-title":"EORTC Quality of Life Group. Cancer-specific utility instrument for health economic evaluations: a synopsis of the EORTC QLU-C10D user manual and current validity evidence","volume":"217","author":"Seyringer","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111645_b0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111645_b0060","doi-asserted-by":"crossref","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558-1565. doi: 10.1200\/JCO.19.00201. Epub 2019 May 8. PMID: 31067138; PMCID: PMC6599408.","DOI":"10.1200\/JCO.19.00201"},{"key":"10.1016\/j.radonc.2026.111645_b0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2024.03.003","article-title":"Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a phase II study","volume":"81","author":"Choi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2026.111645_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2018.08.027","article-title":"Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer","volume":"103","author":"Sutera","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111645_b0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clon.2023.11.041","article-title":"Prospective longitudinal assessment of quality of life after stereotactic ablative radiotherapy for oligometastases: analysis of the population-based SABR-5 phase II trial","volume":"36","author":"Cruz-Lim","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111645_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110466","article-title":"Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: an interim analysis of the E2-RADIatE OligoCare cohort","volume":"199","author":"Alongi","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05250","article-title":"Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: a pilot study","volume":"6","author":"Alam","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.radonc.2026.111645_b0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12955-024-02318-y","article-title":"Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-na\u00efve prostate cancer","volume":"22","author":"Nnabugwu","year":"2024","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.radonc.2026.111645_b0095","article-title":"Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort","volume":"45","author":"Bultijnck","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111645_b0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.clon.2024.06.047","article-title":"Stereotactic body radiotherapy for oligoprogression in castration-resistant prostate cancer: early toxicity analysis of the TRAP trial","volume":"36","author":"Patel","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111645_b0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.clon.2024.01.007","article-title":"Predictors of quality of life decline in patients with oligometastases treated with stereotactic ablative radiotherapy: analysis of the population-based SABR-5 phase II trial","volume":"36","author":"Cruz-Lim","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111645_b0115","first-page":"61","article-title":"Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:19:38Z","timestamp":1786796378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S0167814026004846"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111645","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111645"}}